← All trials
NCT05731752
Phase 1Interventional
Includes initial studies to determine the metabolism and pharmacologic actions of drugs in humans, the side effects associated with increasing doses, and to gain early evidence of effectiveness; may include healthy participants and/or patients.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Jun 4, 2020
- Primary completion
- Nov 4, 2023
- Completion date
- Oct 28, 2024
- First posted
- Feb 16, 2023
- Last posted
- Feb 16, 2023
- Enrollment
- 25
- Arms / groups
- 1 / —
- Source
- AACT · ctgov ingestion
Sponsors
- Government of ChinaLead sponsor
- Government of ChinaCollaborator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.